| Nov 12 |
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Ovid Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $0.17M beats by $0.1M
|
| Nov 12 |
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
|
| Nov 8 |
US Penny Stocks To Watch This November 2024
|
| Oct 31 |
Ovid Therapeutics to Host Investor Event
|
| Sep 30 |
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
|
| Sep 26 |
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
|
| Sep 11 |
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
|
| Sep 4 |
Ovid Therapeutics to Present at Upcoming September Investor Conferences
|
| Aug 20 |
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
|
